Equities

Amniotics AB (publ)

Amniotics AB (publ)

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (SEK)0.0039
  • Today's Change0.000 / 2.63%
  • Shares traded110.45k
  • 1 Year change-86.72%
  • Beta--
Data delayed at least 15 minutes, as of May 17 2024 09:54 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Amniotics AB (publ) is a Sweden-based biotech company that develops cell therapy drugs based on mesenchymal stem cells from amniotic fluid in its in-house GMP licensed facility. Amniotics' own marker technology is used to identify and select stem cells for different tissue types; Lung (PulmoStem), Brain (CogniStem), Kidney (NephroStem), Skin (CutiStem). It allows for selecting the type of cell to be used for specific tissue. The company has developed a process - patented in all steps - which includes collection of amniotic fluid, with a medical device developed by Amniotics, followed by sorting and propagation of stem cells and packaging of product in ampoules in its own GMP facility. Amniotics is a technology and service provider to Universities, Hospitals, and the Biopharmaceutical industry.

  • Revenue in SEK (TTM)0.00
  • Net income in SEK-30.87m
  • Incorporated2015
  • Employees6.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Bio Vitos Pharma AB2.98m-12.87m3.71m1.00--0.96497.231.24-0.2547-0.25470.05330.11190.09890.005.382,983,990.00-42.63-31.11-44.50-32.92100.00---431.21-1,026.764.27--0.00--126.97--13.64------
European Institute of Science AB686.00k-2.76m5.15m0.00--1.97--7.51-4.23-4.231.051.930.24351.249.46---97.91-93.04-105.11-103.1459.3367.01-402.04-518.825.70--0.00--13.698.540.4062------
QuiaPEG Pharmaceuticals Holding AB0.00-16.52m5.50m8.00--0.3605-----3.51-3.510.000.20470.00-------50.53-95.67-100.54-207.86--262.59---5,002.50---15.340.00------17.75--47.06--
XP Chemistries AB663.69k-8.04m5.79m2.00--0.2255--8.73-0.2846-0.28460.02130.2750.0230.20845.99331,845.00-27.79---29.36--50.57---1,211.24--5.79--0.00---37.14---1.55------
2cureX AB155.00k-30.82m6.18m----0.4513--39.86-1.75-1.750.00880.77770.0048--0.0838---95.89-38.21-108.66-43.48-6,889.68-22,153.06-19,883.23-38,685.30---46.08----72.22---3.52------
Lipidor AB77.00k-11.49m6.81m--------88.44-0.3964-0.39640.0027-0.32230.0084--5.31---124.54-59.41---75.10-----14,916.88-643.36--------73.33-20.3372.24------
Stayble Therapeutics AB0.00-23.74m8.36m3.00--0.5063-----0.9492-0.94920.000.52040.00----0.00-116.21-78.64-141.76-95.58------------0.049------3.22------
Eurocine Vaccines AB5.00k-15.06m8.71m3.00------1,742.53-0.1472-0.14720.00005-0.00180.0007--0.002---199.76-83.17-323.19-97.89-199,780.00---301,180.00--------------8.95------
Carbiotix AB (publ)1.47m-13.48m8.83m10.00--0.1284--6.03-0.302-0.3020.03240.38170.0586--2.36146,552.00-53.88-49.38-64.85-55.50235.45574.69-919.76-1,828.86---76.280.1384--259.56-12.04-10.02--13.64--
Amniotics AB (publ)0.00-30.87m10.66m6.00--0.6803-----0.0374-0.03740.000.00570.00----0.00-112.25-101.09-362.71-149.92--------1.12-16.17--------35.75------
Diagonal Bio AB23.00k-11.68m13.62m4.00--0.1056--592.25-0.1982-0.19820.00040.32210.0007--2.005,750.00-37.35---44.49---41,604.35---50,769.57--0.5105-104.20-----88.67--27.75------
Data as of May 17 2024. Currency figures normalised to Amniotics AB (publ)'s reporting currency: Swedish Krona SEK
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.